Jason G. Gall - Concepedia

Author

Jason G. Gall

Also Known As

Haley Fuller, J Gall, J. G. Gall, J.G. Gall, J.G.D. Gall, Jason G D Gall, Jason G Gall, Jason G. D Gall, Jason G. D. Gall, Jason G. Gall

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases GenVec Fred Hutch Cancer Center Hearst (United States)

About

Jason G. Gall is an author at National Institutes of Health specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	33	2K
2	Allergy	6	6	640
3	Natural Sciences	3	3	127
4	Engineering	1	1	33
5	Biology	1	1	55

Jason G. Gall

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
A proof of concept for structure-based vaccine design targeting RSV in humans Michelle C. Crank, Tracy J. Ruckwardt, Man Chen, Science	2019	323
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector Andrew Catanzaro, Richard A. Koup, Mario Roederer, The Journal of Infectious Diseases	2006	313
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes Jason G. Gall, A Kass-Eisler, Leslie A. Leinwand, Journal of Virology Viral PathogenesisImmunologyMolecular BiologyAdenovirus Type 5Viral Structural Protein	1996	239
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial Katherine V. Houser, Grace Chen, Cristina Carter, Nature Medicine VaccinologyVaccine SafetyVaccinationCross-protectionVaccine Development	2022	153
Circumventing the immune response to adenovirus-mediated gene therapy. A Kass-Eisler, Leslie A. Leinwand, Jason G. Gall, PubMed	1996	134
Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors Keith B. Elkon, Chau-Ching Liu, Jason G. Gall, Proceedings of the National Academy of Sciences	1997	132
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Richard L Wu, Azza H. Idris, Nina M. Berkowitz, New England Journal of Medicine	2022	114
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling Kylie M. Quinn, Daniel E. Zak, Andréia da Silva Costa, Journal of Clinical Investigation Adaptive Immune SystemImmunologyAdenoviral Vaccine PotencyImmunologic MechanismCd4 T Cell Responses	2015	110
Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization Kylie M. Quinn, Andréia da Silva Costa, Ayako Yamamoto, The Journal of Immunology Adaptive Immune SystemImmunologyImmunodominanceCd4 T Cell ResponsesImmunotherapeutics	2013	108

Page 1